Drug Profile
DZ 2384
Alternative Names: DZ-2384Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Diazon Pharmaceuticals
- Developer Diazon Pharmaceuticals; McGill University
- Class Antineoplastics; Heterocyclic compounds with 4 or more rings; Oxazoles
- Mechanism of Action Tubulin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for preclinical development in Pancreatic-cancer in Canada
- 28 Dec 2020 No recent reports of development identified for preclinical development in Triple negative Breast-cancer in Canada
- 22 Nov 2016 New profile created from MR 9207341